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Background: Visceral leishmaniasis (VL) is a deadly parasitic diseases caused by Leishmania donovani; it is a major
health problem in many countries. A lack of proper understanding of the disease biology, poor diagnostic methods
and increasing drug resistance are the main reasons for the growing burden of VL infection. Comparative plasma
proteomics are a relatively useful technique that can be used to investigate disease-associated alterations that can
help in understanding host responses against pathogens, and might be useful in disease management and diagnosis.
Result: In this study, a comparative proteomics and glycoproteomics approach using 2DE and 2D-DIGE was employed
between early diagnosed VL patients of all age groups and healthy endemic and non-endemic controls in order
to aid the recognition of disease-associated alterations in host plasma. Comparative proteomics was performed
by the depletion of seven highly abundant plasma proteins. Comparative glycoproteomics was performed by the
depletion of albumin and IgG, followed by purification of plasma glycoproteins using a multi lectin affinity column. From
these two approaches, 39 differentially expressed protein spots were identified and sequenced using MALDI-TOF/TOF
mass spectrometry. This revealed ten distinct proteins that appeared in multiple spots, suggesting micro-heterogeneity.
Among these proteins, alpha-1-antitrypsin, alpha-1-B glycoprotein and amyloid-A1 precursor were up-regulated, whereas
vitamin-D binding protein, apolipoprotein-A-I and transthyretin were down-regulated in VL. Alterations in the levels of
these proteins in VL-infected plasma were further confirmed by western blot and ELISA.
Conclusions: These proteins may be involved in the survival of parasites, resisting neutrophil elastase, and in their
multiplication in macrophages, potentially maintaining endogenous anti-inflammatory and immunosuppressive
conditions. Consequently, the results of this study may help in understanding the host response against L.donovani,
which could help in the discovery of new drugs and disease management. Finally, these alterations on protein levels
might be beneficial in improving early diagnosis considering those as biomarkers in Indian VL.
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mass spectrometryIntroduction
Visceral leishmaniasis (VL), caused by Leishmania dono-
vani, is a parasitic diseases that can be fatal if left un-
treated. Approximately 10 million people are affected
currently and 350 million worldwide are known to be at
risk, primarily in 88 endemic tropical, subtropical and
Mediterranean countries. Amongst these countries, >90%
of cases occur in India, Bangladesh, Nepal, Sudan and* Correspondence: chitra_mandal@yahoo.com
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unless otherwise stated.Brazil. Approximately 100,000 people become newly in-
fected in India each year [1,2].
Owing to its complex manifestation and symptomatic
resemblance, coupled with cross-reactivity with malaria
and tuberculosis, diagnosis of VL is very problematic.
Undiagnosed patients serve as a parasite reservoirs for
disease transmission. Additionally, increasing rates of re-
sistance against known drugs is becoming a problem.
Consequently, considering the growing burden of VL, it
is essential to better understand the disease biology and
host responses against the pathogen, which could help
in the discovery of new ways to manage the disease.
Plasma is the most logical sample to use in the identi-
fication of the disease. Owing to its physiological and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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studies of plasma proteins provide significant insight into
disease progression and pathology, as well as biomarker
discovery and the identification of new drug targets for
disease management [3,4]. Accordingly, alterations in VL
plasma proteins were investigated by performing a com-
parative proteomic and glycoproteomic study using 2DE
and 2D-DIGE between a large number of VL patients of
all age groups, including children, with both endemic and
non-endemic controls. The results revealed several VL-
associated changes in the expression of glycoproteins and
non glycosylated proteins in patient samples, which may
have a role in disease progression and diagnosis.
Results
Reduction in the complexity of plasma proteins through
the depletion of seven highly abundant proteins
When utilizing a comparative proteomics approach, sample-
to-sample variations, diverse heterogeneity of glycopro-
teins and difference in protein abundance are some of
the problems when studying disease-associated changes
in plasma [3]. Therefore, to reduce the biological varia-
tions and dynamicity of different protein abundance,
plasma samples were pooled and seven proteins of high
abundance were subsequently depleted (Figure 1A).
The results clearly illustrate the depletions at marked
areas 2, 5 and 7, with enrichment visible at marked
areas 1, 3, 4 and 6 in the depleted fraction (Figure 1B).
A 2DE analysis of the crude and depleted plasma fur-
ther demonstrated the depletions, enrichments and the
appearance of new co-migrating low-abundance pro-
teins (marked in Figure 1C). These results suggest that
the dynamicity in the abundance of plasma proteins
was lowered markedly, although a complete depletion
was not achieved, with some high-abundance proteins
remaining in compact associations with low-abundance
proteins.
Comparative proteomic analysis of depleted plasma
samples demonstrated VL-associated alterations in 25
protein spots
The successful depletion of highly abundant plasma pro-
teins from all pooled VL and control (endemic/non-en-
demic) samples prompted an investigation into whether
these depleted plasma samples contain any changes in
the expression of VL-associated proteins. Consequently,
all depleted plasma samples were first resolved using
2D-PAGE within a 3–10 linear pI range, before being sil-
ver stained (Additional file 1). The results indicated that
while the protein profile showed reproducibility, it was
still difficult to compare protein spots owing to poor
resolution across the large pI range. Subsequently, a 4–7
linear pI range was selected to provide better resolution
and to specifically select only those spots that were up-or down-regulated in VL. By way of visual comparison,
seven up-regulated spots indicated as 1–7 (Figure 2A)
were identified in the VL samples in comparison with
the endemic and non-endemic controls and therefore could
be considered as VL-associated alterations. For further con-
firmation, plasma samples were analysed using a more sen-
sitive 2D-DIGE with the same pI range. Differential-in-
gel analysis (DIA) of VL against the endemic controls
(Figure 2B) and VL against the non-endemic control
(Figure 2C) revealed that the previously observed (Figure 2A)
seven protein spots were significantly up-regulated in
VL (marked as 1–7). Moreover, DIA was used to pro-
vide a three-dimensional analytic view (Figure 2D) of
the magnitude of changes (Table 1, column 8–9, upper
half ) of the altered spots, and confirmed the VL-
associated up-regulation of seven plasma proteins.
To resolve the higher molecular weight regions, the
samples were again separated using 2D-PAGE through
further narrowing the pI range (4.7–5.9) and a visual
comparison revealed that the eight proteins present in
spots 1–6, and 9 and 10 were up–regulated, whereas four
proteins in spots 7, 8, 11 and 12 were down-regulated in
VL (Figure 3A).
Additionally, DIA analysis after 2D-DIGE revealed 18
protein spots that were significantly differentially
expressed in VL (Figure 3B,C). Among these proteins,
the previously identified 1–12 protein spots were the
same and expressed in a similar manner as was found in
2DE (Figure 3A). However, spot 7 remained unchanged
following 2D-DIGE analysis. Interestingly, seven new
protein spots were identified, among which 13–17 were
up-regulated, and 18 and 19 were down-regulated sig-
nificantly. Moreover, three dimensional expression pro-
filing (Figure 3D) of the level of changes in expression
(Table 1 column 8–9, lower half ) from DIA confirmed
their association with VL.
Glycoproteomics revealed differential expression of the
fourteen VL-associated glycoprotein spots
Glycosylation of proteins plays an important role in vari-
ous biological processes including the immune response
and cellular regulation [5]. Consequently, the possibility
that any plasma glycoproteins were differentially expressed
in VL was investigated. To achieve this, the most abun-
dant non-glycosylated (albumin) and glycosylated (IgG)
proteins were first depleted from plasma samples, as illus-
trated in Figure 4A, to avoid their interference in glyco-
protein purification. Following this, glycoproteins were
purified from the depleted plasma samples using multi-
lectin affinity chromatography (M-LAC), illustrated in
Figure 4A. Bound and unbound fractions from both
columns were resolved using SDS-PAGE (Figure 4B). A
comparison between lanes 2 and 3 demonstrated deple-
tions at the first and fourth boxed positions and
Figure 1 MARS affinity column depleted high abundance proteins. A. Flow diagram for depletion of seven high-abundance proteins from
human plasma. B. Equal amounts (35 μg) of the total, bound and depleted plasma were loaded in the indicated lane, separated on a gradient
SDS-PAGE gel (7.5-15%), and stained with coomassie blue. Positions 1, 3, 4 and 6 indicate enrichment after depletion, position 2 shows the
appearance of comigrated bands in depleted fraction with high abundance proteins, whereas 5 and 7 positions represent decrease or removal
after depletion. C. Total and depleted plasma (250 μg) were separated on 3–10 pI range IPG strip (17 cm) with 6-18% gradient gel and stained
with coomassie blue. “ [ ” marked portion indicates depletion of proteins while alphabetically marked positions (a, b) indicate the appearance of
some co-migrated spots after depletion.
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tions in the depleted fraction. After this, using the lane
3 fraction, glycoproteins were purified as an M-LAC-
bound fraction (lane 4) and non-glycosylated proteins
were removed as an M-LAC-unbound fraction (lane 5).
Sialic acids present in most of the glycoproteins make
them acidic. Therefore, purified glycoproteins were sepa-
rated using 2DE across a 4–7 pI range. Ten spots
(marked numerically and with arrows) were differentially
expressed in VL in comparison with endemic and non-
endemic controls. Among these, nine spots (1, 2 and 4–10)
were up-regulated and spot 3 was down-regulated(Figure 5A). For further confirmation, samples were again
resolved using 2D-DIGE and were analysed using DIA ana-
lysis. The comparative analysis between VL and endemic
control, and VL and non-endemic control indicated that
15 spots (marked numerically) were significantly differen-
tially expressed in VL (Figure 5B,C). Among these,
spots 1 and 2, and 4–10 were the same and were
expressed similarly as was found using 2DE (Figure 5A),
while spot 3 remained unchanged. Furthermore, the gly-
coproteins present in the newly detected spots 11–14
were up-regulated and 15 was down-regulated in VL; this
result was corroborated using DIA expression profiles
Figure 2 Comparative 2DE and 2D-DIGE analysis in the acidic pI range. A. Equal amount (50 μg) of depleted endemic control, VL and
non-endemic control plasma samples were separated in 4–7 pI range IPG strip (17 cm) followed by SDS-PAGE (6-18%) and silver stained. Differentially
expressed spots were circled with numbers after visual comparison between VL and endemic/non-endemic controls. B. C. Equal amount
(50 μg) of depleted VL and endemic/non-endemic control plasma proteins labeled with CyDyes and separated. Images of VL and control were
taken at different excitation/emission wavelengths and merged with ImageQuant Tool. Differentially expressed spots were marked by numbers
following DIA analysis. D. Zoomed images and the analytic three dimensional expression profile of marked differently expressed spots 1–7.
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glycoproteomic analysis revealed that fourteen protein
spots were differentially expressed in VL.
Identification of 39 differentially expressed VL-associated
protein spots using MALDI-TOF/TOF analysis
VL-associated non-glycosylated and glycosylated protein
spots were sequenced. Tables 1 and 2 reveal that, among
39 different VL-associated protein spots, a few proteinsappeared in multiple spots, suggesting a degree of hetero-
geneity. Finally, amyloid-A1 precursor (SAA1), alpha-1-
antitrypsin (A1AT or SERPINA1), fibrinogen gamma–B
chain precursor, alpha-1-B-glycoprotein (A1BG) and
haptoglobin precursor allele 1, 2 were identified as be-
ing up-regulated, and vitamin-D binding protein (VDBP
or GC), transthyretin (TTR), apolipoprotein A-I (APOA1)
and A-IV were identified as being down-regulated pro-
teins in VL infection (Tables 1, 2).
Table 1 Identification of differentially expressed protein spots in VL
Spot no. Protein name Accession no pI MW in KDa score % of SCa VL/ECb VL/NECb Expression
pI range 4-7
1 Unidentified — ~6.5 ~15 — — 7.51 4.32 ↑
2 Unidentified — ~6.0 ~15 — — 27.08 18.31 ↑
3 Unidentified — ~5.5 ~15 — — 26.57 17.32 ↑
4 Unidentified — ~5.0 ~15 — — 18.82 15.39 ↑
5 Amyloid A1 precursor YLHUS 6.28 13.58 80 52 9.14 7.21 ↑
6 Amyloid A1 precursor YLHUS 6.28 13.58 89 53 8.04 6.10 ↑
7 Unidentified — — — — — 2.66 2.01 ↑
pI range 4.7-5.9
1 α-1-antitrypsin precursor ITHU 5.37 46.88 230 36 2.63 2.12 ↑
2 α-1-antitrypsin precursor ITHU 5.37 46.88 240 49 7.49 6.32 ↑
3 α-1-antitrypsin precursor ITHU 5.37 46.88 230 36 11.29 9.21 ↑
4 α-1-antitrypsin precursor ITHU 5.37 46.88 250 54 7.41 6.37 ↑
5 α-1-antitrypsin precursor ITHU 5.37 46.88 230 36 5.58 5.60 ↑
6 α-1-antitrypsin precursor ITHU 5.37 46.88 392 55 4.30 4.50 ↑
8 Vitamin-D binding protein VYHUD 5.40 54.53 243 45 −3.94 −3.21 ↓
9 Fibrinogen gamma-B chain precursor FGHUGB 5.37 52.11 149 53 2.73 1.89 ↑
10 Fibrinogen gamma-B chain precursor FGHUGB 5.37 52.11 148 53 2.68 1.93 ↑
11 APO A-I protein (frag.) CAA00975 5.27 28.06 390 56 −3.31 −2.93 ↓
12 Transthyretin 2ROYA 5.35 13.24 272 85 −3.96 −3.53 ↓
13 Unidentified — ~5.30 ~30-45 — — 4.93 3.97 ↑
14 Unidentified — ~5.30 ~30-45 — — 6.30 5.32 ↑
15 Unidentified — ~5.30 ~30-45 — — 5.60 4.73 ↑
16 Unidentified — ~5.30 ~30-45 — — 5.83 4.98 ↑
17 Unidentified — ~5.30 ~30-45 — — 4.88 4.54 ↑
18 APO A-IV protein LPHUA4 5.23 45.30 280 54 −4.82 −4.00 ↓
19 APO A-I protein CAA975 5.27 28.06 242 62 −2.68 −2.71 ↓
Differentially expressed protein spots were identified by MALDI-TOF/TOF mass spectrometry. Combined MS and MS/MS results were analyzed by MASCOT and
fold of up/down regulation determined from DIA analysis.
aSC- Sequence-coverage.
bFold of increase and decrease ratio of the differentially expressed proteins from DIA analysis using DeCyder software from three different 2D-DIGE experiments
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the association with VL
The identification of protein–protein interaction net-
works in disease-associated proteins is an important way
for develop system-level understanding of the cellular
mechanisms of VL. Therefore, to speculate further on
the probable biological-association and disease rele-
vance, the interactions of these differentially expressed
plasma proteins was examined. Protein–protein inter-
action analysis of the differentially expressed proteins re-
vealed important connections of those proteins, through
which they could exert their biological roles. Here the
connections of six selected differentially expressedproteins that showed probable biological relevance in
the context of Leishmania infection and disease progres-
sion from the existing evidence are highlighted (Figure 6
A–F, Additional file 2). The analysis demonstrated that
SERPINA1 (A1AT) interacts with a wide variety of pro-
teases and can inhibit their activity (Figure 6A). A1BG
exhibited an interaction with cysteine-rich secretory pro-
tein 3 (CRISP3, Figure 6B). SAA1 interacts with scavenger
receptor class B, member 1 (SCARB1), which maintains
cholesterol balance between the cell surface and extracellu-
lar donors and acceptors (Figure 6C). APOA1 was found
to interact with lecithin-cholesterol acyltransferase
(LCAT), which is important for cholesterol reverse
Figure 3 VL-associated alterations in narrow acidic pI range. A. Depleted VL and endemic/non-endemic control plasma proteins (50 μg)
were focused using 4.7-5.9 pI range IPG strip (17 cm) and followed by SDS-PAGE (6-18%). Gels were silver stained and differentially expressed
spots (1–12) were marked after visual comparison. B. C. Equal amounts (50 μg) of VL and endemic/non-endemic control were labeled by CyDyes
with internal standard and separated as A. Fluorescent images were taken at different excitation/emission wavelengths and marked by numbers
after DIA analysis. D. The magnified images and three dimensional expression profiles of the differentially expressed spots compared to controls
were reported.
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with iron transporter protein transferrin (TF, Figure 6E)
and VDBP was found to interact with complement 5a re-
ceptor 1(C5AR1) and complement 3 (C3), which perform
roles in the innate immune response (Figure 6F).
Confirmation of the differential expression of six
identified proteins by immunoblotting and ELISA
Following this analysis, the differential expression status
of six important proteins that might have a role in
pathogenesis was checked using western blot analysis(Figure 7). The results revealed the up-regulation of
alpha-1-antitrypsin, alpha-1-B glycoprotein and amyloid
A1 precursor, and the down-regulation of vitamin-D
binding protein, apolipoprotein A-I and transthyretin,
which was previously observed using 2DE, 2D-DIGE
and DIA analysis.
Further, this was quantitatively verified by performing
an ELISA using independent plasma, which also sup-
ported significant up- or down-regulation of these pro-
teins (Figure 8, Additional file 3). In summary, it was
concluded that these differentially expressed glycoproteins
Figure 4 Purification of glycoproteins by M-LAC column from albumin and IgG depleted plasma. A. Brief flow diagram of glycoprotein
purification from plasma samples. B. Equal amount (25 μg) of all fractions except total plasma (10 μg) was separated using 7.5-15% SDS-PAGE
and stained with coomassie blue. Boxes 1 and 2 indicate the reduction whereas boxes 2, 3, 5 and 6 indicate the enhancement after depletion.
Underlined bands clearly showed good binding of glycoproteins as well as the depletion of non-glycosylated proteins.
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age groups.
Discussion
Since the dawn of proteomics, efforts have been made to
identify and categorize the plasma proteins because of
their potential utility as disease biomarkers, in thera-
peutic monitoring, and in understanding host responses
to pathogens [3]. However, there are great challenges in
using plasma for proteomic/glycoproteomic analysis be-
cause of their dynamic range of abundant proteins, diverse
heterogeneity, the masking effects of highly abundant pro-
teins, and the very low abundance of some important pro-
teins. Therefore, the depletion of highly abundant proteins
is essential in order to better visualise other important
proteins. Accordingly, highly reproducible and competent
MARS column and aurum serum mini kits were used.
Glycoproteomics is a high-impact subfield of proteomics
from the perspective of its biological and clinical signifi-
cance. The type and structure of glycosylations of a se-
creted or membrane bound protein is highly specific
depending on its physiological state and alter in different
disease conditions [6]. Accordingly, the major findings
of this study include the identification of VL-associated
non-glycosylated and glycosylated proteins through
comparative plasma proteomics/glycoproteomics, andthe establishment of their probable biological relation-
ship from protein–protein interaction network.
In this study, 2DE and quantitative 2D-DIGE prote-
omic technology was utilized. DIGE technology maxi-
mizes the probability of gel-to-gel reproducibility and
the number of spots detected in comparison with con-
ventional 2DE; it also provides reliable quantification.
To minimize the complexity of biological variations of
plasma, pooled samples of VL and endemic/non-en-
demic controls were used. Here, a total of ten differentially
expressed (six up-regulated and four down-regulated) VL-
associated proteins were identified across all age groups.
Among these proteins, A1AT, A1BG and SAA1 were up-
regulated, where as VDBP, TTR and APOA1were down-
regulated. These VL-associated altered proteins may have
the potential to serve as candidate biomarkers.
An interactome study revealed that A1AT interacts
with a wide variety of proteases and can inhibit their ac-
tivity; consequently, it helps to protect tissues from en-
zymes of inflammatory cells, in particular neutrophil
elastase. As a result, over-expression of A1AT precursor
may provide protection for a parasite from neutrophil
elastase during the process of infection. Although the
up-regulation of A1AT was reported only in infantile
samples, this was confirmed in all VL patients irrespect-
ive of their ages [7].
Figure 5 Comparative glycoproteomics using 2DE and 2D-DIGE analysis. A. Equal amounts (50 μg from each) from VL and controls
(endemic/non-endemic) were separated using 4–7 linear pI range IPG strip (17 cm) and SDS-PAGE (6-18%). The gels were silver stained and
differential expressions of VL glycoproteins compared to both endemic and non-endemic control were marked with an arrow and number after
visual comparison. B. C. Purified glycoproteins (50 μg) from VL and endemic/non-endemic controls were labeled with CyDyes with corresponding
internal standard and separated as A. Gels were scanned in different excitation/emission wavelengths and Cy3 and Cy5 images were merged
using ImageQuant tool. Differently expressed spots were marked by numbers. D. Zoomed images of differentially expressed spots and 3D
expression profile of the same after DIA analysis.
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member of the immunoglobulin superfamily; however,
its function is unknown. Other than four glycosylation
sites, N-acetylation and glycation are the two main post-
translational modifications reported in this protein [8,9].
It is highly expressed in the adult and fetal liver however
found in minute level in the blood, brain, lung, lymph
node, ovary, testis and pancreas. Up-regulation of A1BG
was observed in various types of cancer like pancreatic
ductal carcinoma, liver and lung cancer [10-12]. In thisstudy, A1BG was identified, for the first time, as being
augmented in VL plasma. The study reveals that it inter-
acts with CRISP3 and acts as a receptor to it [13]. As
CRISP3 is expressed in neutrophils and is involved in
the innate immune response, the A1BG–CRISP3 inter-
action may perform a role in immune suppression,
which warrants further investigation.
The up-regulation of an acute phase protein, SAA1, is
significant because it suggests an early stage of infection.
SAA1 is a component of high-density lipoprotein (HDL)
Table 2 Identification of VL associated differentially expressed glycoprotein spots
Spot no. Protein name Accession no pI MW in KDa score % of SCa VL/ECb VL/NECb Expression
1 α1-B glycoprotein OMHU1B 5.65 52.48 112 34 2.24 2.01 ↑
2 α1-B glycoprotein OMHU1B 5.65 52.48 123 38 2.06 2.00 ↑
4 Unidentified — ~6.1 ~38 — — 2.01 1.92 ↑
5 Haptoglobin precursor, allele-1 HPHU1 6.13 38.94 105 34 2.18 2.30 ↑
6 Haptoglobin precursor, allele-1 HPHU1 6.13 38.94 157 34 2.39 2.49 ↑
7 Haptoglobin precursor, allele-1 HPHU1 6.13 38.94 152 34 2.76 2.02 ↑
8 Haptoglobin precursor, allele-2 HPHU2 6.13 45.86 68 24 3.68 3.69 ↑
9 Haptoglobin precursor, allele-2 HPHU2 6.13 45.86 98 21 3.13 2.79 ↑
10 Haptoglobin precursor, allele-2 HPHU2 6.13 45.86 117 28 3.81 2.67 ↑
11 Unidentified — ~5.5 ~53 — — 2.24 2.00 ↑
12 Unidentified — ~6.1 ~38 — — 2.87 2.65 ↑
13 Haptoglobin precursor, allele-1 HPHU1 6.13 38.94 138 37 3.43 2.57 ↑
14 Unidentified — ~6.1 ~45 — — 3.60 2.97 ↑
15 Unidentified — ~6.2 ~25 — — −3.12 −2.78 ↓
Differentially expressed glycoprotein spots were identified by MALDI-TOF/TOF mass spectrometry. Combined MS and MS/MS results were analyzed by MASCOT
and fold of up/down regulation were determined from DIA analysis.
aSC- Sequence-coverage.
bFold of increase and decrease ratio of the differentially expressed proteins from DIA analysis using DeCyder software from three different 2D-DIGE experiments
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quently, this may be one of the reasons for APOA1
down-regulation. The result indicates that it interacts
with SCARB1, a receptor of phospholipids, cholesterol
esters and lipoproteins, and maintains the flux of free
and esterified cholesterol between the cell surface and
extracellular donors and acceptors. Macrophage mem-
brane cholesterol plays an important role in parasite in-
fectivity [14] so the up-regulation of SAA1–SCARB1
interactions may help in the development of VL
infection.
Similarly, APOA1 was found to be down-regulated in
VL patients in all age groups. It is the main component
of HDL and is involved in the reverse transport of chol-
esterol from tissues to the liver for degradation, prevent-
ing its accumulation in macrophages through an
interaction with LCAT. As such, the down-regulation of
APOA1 may increases the level of macrophage choles-
terol, which further assists parasite infectivity [14]. The
down-regulation of these proteins was also observed in
infants, indicating their VL-association [7,15].
TTR was also found to be down-regulated like earlier
report [16]. TTR, a carrier of thyroxine and retinol, se-
creted by hepatocytes, may act as an endogenous anti-
inflammatory mediator. It was observed that TTR inter-
acts with iron-binding transport proteins (TF). Through
modulating this interaction, a parasite might alter the
host iron metabolism in favour of themselves, helpingtheir proliferation within macrophages [17]. The result
also indicated that an interaction occurs between TTR
and APOA1, which is also down-regulated in VL
plasma.
The interaction of VDBP with C5AR1 and C3 suggests
that it has a role in inflammation, enhancing the chemo-
tactic activity of complement 5a for neutrophils and acti-
vating macrophages [18], critical for the establishment of
the early infection and subsequent propagation. Interac-
tions with C3 may also modulate the innate immune re-
sponse against parasites. Consequently, significant down-
regulation of VDBP may delay the immune response
against VL, thereby helping in the survival and multiplica-
tion of the parasite within macrophages. Taken together,
all of these identified VL-associated proteins may provide
a basic mechanism by which a parasite can survive in its
host, although further investigation is required.
This study opens up new avenues for future explor-
ation. Since VL is a poor man disease, therefore based
on our result a simple and easily affordable diagnostic
method using these differentially expressed proteins re-
quired to be developed to check in field conditions. Lon-
gitudinal study is also needed to evaluate their potential
as prognostic marker. Additionally, distinct expression
levels of A1AT in multiple spots demonstrates hetero-
geneity of glycoproteins, indicating an altered appear-
ance of specific glycan structures in VL conditions.
Glycan analysis to differentiate the structures present in
Figure 6 Protein-protein interaction networks. Protein-protein interactors of six differentially expressed protein (A) alpha-1-antitrypsin (SERPINA1),
(B) alpha-1-B glycoprotein (A1BG), (C) amyloid A1 precursor (SAA1), (D) apolipoprotein A-I (APOA1), (E) transthyretin (TTR) and (F) vitamin-D binding
protein (GC). The differentially expressed proteins indicated in the middle of every cluster with red and other interactors (gene names) with different
colors. Purple and green colored lines for experimental and textmining evidence of different interactions.
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of future studies. One futuristic approach will be to de-
velop a monoclonal antibody against that particular gly-
cotope (spot 3 of A1AT), which may pave the way for
better diagnostic tools for VL. While most of the highly
abundant proteins were found to be depleted in thisFigure 7 Confirmation of differential expression of six proteins
by western blot. Western blot analysis illustrated the up-regulation
of alpha-1-antitrypsin, alpha-1-B glycoprotein, Serum amyloid A1 and
down-regulation of apolipoprotein A-I, transthyretin and vitamin-D
binding protein in individual VL samples compared to endemic (EC)
and non endemic controls (NEC).study, the identification of any changes in these proteins
remains to be investigated. There are many connections
in the protein–protein network other than those
highlighted in relation to VL. Establishing the import-
ance of these interactions requires further research.
Conclusions
Comparative proteomic/glycoproteomic approaches within
different sub-proteome levels and pI ranges helps to over-
come the vast complexity of dynamic abundance and the
heterogeneity of plasma proteins. This study illustrated sig-
nificant alteration of A1AT, A1BG, SAA1, VDBP, APOA1
and TTR in VL plasma. In view of the growing burden of
VL, these six proteins either independently or in combin-
ation may be useful as diagnostic/prognostic biomarkers
and understanding parasite survival in the hostile environ-
ment of the host. Additionally, future experiments using
particular glycotopes of A1AT may help in the early diag-
nosis of VL across all patient age groups, even when the
parasite remains undetected in the spleen/bone-marrow.
Methods
Plasma samples
VL plasma samples of all age groups, including male
and female, were collected from Kala-Azar Medical





Individuals 34 12 15
Age range (Yr) 6-55 15-38 22-30
male: female 19:15 7:5 9:6
Child (≤10 yr): adult ratio 28:6 NA NA
Duration of illness (days)a 60 ± 15 NA NA
Splenic amastigote scorea,b 1.6 ± 0.6 NA NA
Spleen size (cm)a 5.37 ± 1.53 NA NA
Hemoglobin conc (g/dl)a 8.1 ± 1.3 11.3 ± 1.2 12.4 ± 0.85
RBC count (106/μl)a 2.95 ± 0.77 4.1 ± 1.1 5.1 ± 0.96
aData are represented as mean ± SD.
NA- Not Applicable.
bSplenic amastigote score indicated as 4, >1 to 10 parasites/field; 3, >1 to 10
parasites/10 fields; 2, >1 to 10 parasites/100 fields; 1, >1 to 10
parasites/1,000 fields;
Figure 8 Quantitative analysis of differentially expressed proteins. Quantitative expression of differentially expressed six proteins, namely
alpha-1-antitrypsin (A1AT), alpha-1-B glycoprotein (a1BG), amyloid A1 precursor (SAA1), apolipoprotein A-I (APOA1), transthyretin and vitamin-D
binding protein in VL plasma in comparison to endemic (EC) and non endemic controls (NEC). A significance level of up or downregulation are
indicated as “*” above the compared group.
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ical Medicine (STM), India (n = 5) after confirmation
of VL by microscopic demonstration of amastigotes in
bone marrow/splenic aspirates, as per WHO recommen-
dations [19]. Both endemic (n = 12) and non-endemic
healthy control (n = 15) samples were included. To
search disease-associated alterations that can help in
understanding host responses against pathogens, and
might be useful in disease management and diagnosis,
those patients who had a low spleen parasitic load or
for whom parasites were detected after a few days
by in vitro splenic aspirate culture were selected
(Table 3). Blood was collected using an EDTA vacutai-
ner, incubated for 20–30 min at 4°C and centrifuged
at 2000–2500 × g for 15 min. Plasma was separated
and stored with a protease inhibitor at −80°C in small
aliquots.
The study was approved by the Institutional Ethical
Committee of Council of Scientific and Industrial
Research- Indian Institute of Chemical Biology, Kolkata,
India. The patient samples were collected from the Kala-
Azar Medical Research Centre, Muzaffarpur, Institute of
Medical Sciences, Banaras Hindu University, Varanasi
and School of Tropical Medicine, Kolkata, India, with
ethical approval from respective centres/institutes. The
samples were collected with written informed consent
from all participants/parents/guardians.Sample preparation
To reduce the complexity due to biological variation of
samples and to have a reasonable sample size for two di-
mensional gel electrophoresis (2DE) and two dimen-
sional differential in-gel electrophoresis (2D-DIGE)
analysis, VL samples (n = 34) were reduced to seven
pooled samples containing five different plasmas, except
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non-endemic (n = 15) controls were pooled separately to
make four and five samples, respectively, containing three
different plasma samples from each group (Table 3).
Depletion of high abundance proteins
Seven high abundance proteins (albumin, transferrin,
haptoglobin, antitrypsin, IgG, IgA and fibrinogen) were
depleted from pooled plasma using a multiple affinity
removal system HPLC column (4.6 × 100 mm, MARS)
according to the manufacturer’s instructions (Agilent
Technologies, USA) [20]. In brief, crude plasma (50 μL)
was diluted five-fold with equilibration buffer A before
being filtered through a 0.22-μm micro centrifuge filter
and injected into the antibody column using an HPLC
system (Shimadzu, Germany). The flow-through frac-
tions from sequential injections were collected, pooled
and concentrated to a volume of 200 μL using a 5-kDa
MWCO spin concentrator; samples were stored in small
aliquots at −80°C. The column was routinely regenerated
by eluting bound high-abundance proteins with buffer B
and, subsequently, the column was neutralized with buf-
fer A before further use. The flow-through fraction was
used for total proteome study.
Isolation of plasma glycoproteins
Albumin and IgG were first depleted using the aurum
serum protein mini kit (Bio-Rad, CA) [21]. Glycopro-
teins were purified from this depleted plasma using a
multi lectin affinity chromatography (M-LAC) column
by mixing 0.50 mL each of agarose-bound ConA, WGA
and Jacalin lectin in a PD-10 disposable column (GE-
Healthcare, USA). WGA binds to a terminal N-acetyl-
glucosamine (dimer or trimer) attached to a common
type of glycoprotein present in plasma. Similarly, Jacalin
is another lectin and exhibits specificity towards O-gly-
cosidically linked oligosaccharides containing galactosyl
(β-1, 3) N-acetylgalactosamine (even in a mono or disia-
lylated form). ConA recognizes the most commonly oc-
curring sugar structure, α-linked mannose. Therefore,
the combination of these three lectins would be ex-
pected to capture almost all types of commonly available
N and O-linked glycoproteins present in the plasma. De-
pleted plasma (100 μL) was diluted to a volume of
1.0 mL with equilibrium buffer (20 mM Tris, 0.15 M
NaCl, 1.0 mM MnCl2 and 1.0 mM CaCl2, pH 7.4) before
being added to a pre-equilibrated column and incubated
for 2 hr at a temperature of 4°C. The flow through frac-
tion was collected as the non-glcosylated fraction. After
washing three times with equilibration buffer, the bound
fraction was eluted with 5 mL of elution buffer containing
20 mM Tris, 0.50 M NaCl, 0.20 M methyl-α-D-mannopyr-
anoside, 0.20 M methyl-α-D-glucopyranoside, 0.50 M
N-acetylglucosamine and 0.80 M galactose, pH 7.4. Thebound fraction was concentrated using a 5-kDa MWCO
spin concentrator before being stored as the purified gly-
coproteins in small aliquots at a temperature of −80°C for
later use [22].Two dimensional gel electrophoresis (2DE), staining and
imaging
Protein concentrations were estimated using a quick-
start Bradford kit [23]. The required quantities of pro-
teins were precipitated to remove interfering materials
using a 2D-clean up kit (Bio-Rad) and resolubilised in
rehydration buffer (7 M urea, 2 M thiourea, 2% CHAPS,
0.2% w/v ampholytes, 50 mM DTT and 0.004% bromo-
phenol blue). An IPG-strip (Bio-Rad) of required pI/
length was passively rehydrated with the resolubilised
sample for 18 hr and focused using PROTEAN-IEF
(Bio-Rad). The focused IPG-strips were equilibrated for
30 min each using equilibration buffer-I (6 M urea, 2 M
thiourea, 0.375 M Tris–HCl, pH 8.8, 20% glycerol, 2%
SDS, 0.005% bromophenol blue and 2% DTT) followed
by buffer-II (2.5% iodoacetamide in place of DTT). The
strips were then sealed on top of a gradient polyacryl-
amide gel with 0.5% agarose in electrophoresis buffer
and separated using Bio-Rad gel apparatus [21,24].
Gels were silver stained for visualization and were
subjected to MALDI-compatible colloidal coomassie/
bio-safe coomassie staining for sequencing [25,26]. The
gels were scanned using a Pro-Pic-II (Genomic solu-
tion, USA) image scanner and stored in 1% acetic acid
at a temperature of 4°C.Two dimensional differential in-gel electrophoresis
(2D-DIGE), imaging and analysis
Proteins were precipitated and resolubilised in DIGE-
labelling buffer (7 M urea, 2 M thiourea, 4% CHAPS,
30 mm Tris–HCl, pH 8.5). Control, VL and internal
standard samples (50 μg/15 μL) were labelled with three
different CyDyes (GE-Healthcare) [27]. The pooled sam-
ple was rehydrated with rehydration buffer (7 M urea,
2 M thiourea, 2% CHAPS, 0.2% w/v ampholytes, 50 mm
DTT) for 30 min using mild shaking in the dark. The
mixed sample was resolved two dimensionally with min-
imal exposure to light.
The gel was scanned at three different excitation/emis-
sion wave lengths using Typhoon trio; images were then
visualized and merged using ImageQuant tools (GE
Healthcare). Differential expression patterns between the
control and patient samples were statistically analysed using
DeCyder v5.0 software (GE-Healthcare) by differential in-
gel analysis (DIA). Spots from non-protein particles and
background were filtered out and spots having a ≥2.0-fold
increase or decrease with a p-value <0.05 were reported.
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MALDI-TOF/TOF mass spectrometry
Protein spots were picked from the biosafe-coomassie-
stained gel using a wide-bore tip head, and from
fluorescent-stained gel using an automated spot picker
(Pro-Pic-II). The excised gel pieces were destained and
digested using the In-Gel-Digestion kit (Pierce) according
to the manufacturer’s instructions. Concentrated peptides
were desalted using ZipTip (Millipore) and eluted with
50% acetonitrile (4 μL) in 0.1% trifluoro-acetic acid (TFA).
Eluted peptides were spotted onto the MALDI target
plate using the matrix-sample-matrix sandwich method
using α-cyano-4-hydroxy cinnamic acid (5.0 mg/mL,
Sigma) in 70% acetonitrile in 0.1% TFA. The mass
spectrum of the digested peptides was measured using a
4700 MALDI-TOF/TOF analyser (Applied Biosystem,
USA) in reflector mode. Before acquiring peptide mass
spectrum from the sample, the system was calibrated
using a standard 4700 Calmix (des-Arg 1-Bradykinine;
904.468, Angiotensin 1; 1296.685, Glu-1-fibrinopeptide
B; 1570.677, ACTH 1–11; 2093.087, ACTH 18–39;
2465.199, ACTH 7–38; 3657.929). The mass spectrum
was filtered between 800–4000 Da with a signal-to-noise
ratio of 25 for generating the pick list using 4000 series
explorer v3.5 software. To identify the acquired peptide
spectrum, a search was performed using the parameters:
Homo sapiens, maximum number of miss cleavage 1,
mass tolerance 100 ppm, carbamidomethylation of cyst-
eine, partial N-terminal acetylation, partial methionine
oxidation and modification of glutamine as fixed modifi-
cation of peptides. All the data were analysed using GPS
explore v3.0 (TM) software and a search was performed
of the combined MS and MS/MS results using the
NCBInr, SWISS PORT and MSDB databases using MAS-
COT software v2.1 in order to identify the proteins. The
identification was based on significant MASCOT Mowse-
score (p < 0.05) and a comparison of observed versus ex-
pected pI and molecular weight from the 2DE gel.
Protein-protein interaction analysis
An analysis of the protein–protein interactions of differ-
entially expressed plasma proteins was performed using
STRING v9.1 software. STRING is a database and web
search tool of predicted and known protein–protein in-
teractions. The physical (indirect) and functional (direct)
interactions are considered when establishing the links,
which are derived from genomic context, high-throughput
experiments, co-expression analysis and previous literature
resources. Here, experimental and textmining resources
were used as a prediction method and the confidence score
(≥0.700) as the parameter of interaction analysis. Nodes
were coloured in the case of direct interaction with the in-
put and white was used where it was absent. Two different
size of the node reflect that there is structural informationavailable for the protein (big, i.e., it is larger to fit the
thumbnail picture) or not (small). Edges, the predicted
functional links are the evidence of interactions between
two proteins. Purple and green coloured edges represent
the experimental and literature mining evidence of the
interaction. The network is represented in confidence view,
but action view was also used in the case of biological rele-
vance analysis [28].
Western blot analysis
Albumin and IgG depleted-plasma proteins (50 μg) were
separated by SDS-PAGE (12%) and electro-transferred
onto nitrocellulose membranes. The membrane was
blocked using TBS-BSA and probed with a primary anti-
body overnight at a temperature of 4°C. After washing,
the HRP-conjugated secondary antibody was added and
the membrane was developed using the ECL system
(Thermo scientific).
Enzyme-linked immunosorbent assay (ELISA)
The expression status of the proteins of interest were quan-
titatively compared between the endemic control, non-
endemic healthy control and VL plasma samples using an
ELISA kit following the manufacturer’s supplied protocol.
A separate ELISA kit was used for alpha-1-antitrypsin,
amyloid A1 precursor, vitamin-D binding protein, apolipo-
protein A-I, transthyretin (Immunology Consultant Labora-
tory, Inc.) and alpha-1-B glycoprotein (Uscn Life Science
Inc.). The sample population used for this quantitative ana-
lysis was a new set of independent samples and was differ-
ent from those used for the proteomic analysis.
Statistical analysis
Statistical analysis was performed using Graph Pad Prism
5 and Microsoft Excel software. The differences between
the groups were analysed using at-test or Mann–Whitney
U-test. Data represented in the tables were from at least
three independent experiments with p < 0.05. In case of
ELISA, standard error bars represent the standard error of
the mean (±SEM) and significance of p value is repre-
sented as“***” (p < 0.001) or “**” (p < 0.01).Additional files
Additional file 1: Comparative 2DE between endemic control vs VL
and non-endemic control vs VL. Equivalent amount (300 μg) of MARS
column high abundant protein depleted endemic control, VL and
non-endemic control plasma were separated and processed as discussed
in Figure 1C.
Additional file 2: Predicted protein-protein interactors of six
VL-associated proteins.
Additional file 3: Sample population and quantitative ELISA data.
VL associated differential expression of plasma protein were quantitatively
determined by ELISA in comparison to NEC and EC. Quantitative expression
data of six proteins were represented as Mean ± SEM in three sets.
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